Position in LGND
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$3,723,672
+$980,645 QoQ
Shares Held
18,651
+28.6% QoQ
Ownership
0.093%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CAXTON ASSOCIATES LLP holds $37,379,798 across 16 Biotechnology names. LGND ranks #3 (10.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
36,026 | $16,087,050 | |
| 2 | TERN |
Terns Pharmaceuticals, Inc.
|
94,724 | $4,993,849 | |
| 3 | LGND |
Ligand Pharmaceuticals Inc
This page
|
18,651 | $3,723,672 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
49,308 | $2,785,408 | |
| 5 | ARVN |
Arvinas, Inc.
|
260,016 | $2,756,169 | |
| 6 | ABVX |
Abivax S.A.
|
24,750 | $2,755,912 | |
| 7 | TARS |
Tarsus Pharmaceuticals, Inc.
|
15,163 | $1,063,684 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
4,311 | $728,645 |
All Filings in LGND
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,723,672 | 18,651 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $2,743,027 | 14,508 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2,569,947 | 14,508 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||